Utility of brain FDG-PET in primary CNS lymphoma.
18Fluoro-deoxyglucose positron emission tomography (FDG-PET) imaging has been widely incorporated into the management of systemic non-Hodgkin lymphoma. However, its utility in primary central nervous system lymphoma (PCNSL) is unclear. We report 28 PCNSL patients who underwent brain FDG-PET to inform clinical management. Baseline PET imaging demonstrated hypermetabolism consistent with aggressive lymphoma in 75% (9/12) of patients. FDG-PET used for response assessment or the interpretation of nonspecific magnetic resonance imaging abnormalities showed hypermetabolism in 50% (10/20) of patients, which was important in guiding further management. This data suggests that FDG-PET imaging in PCNSL is useful and may have a role in response assessment.
Mohile
Nimish A
NA
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Deangelis
Lisa M
LM
Abrey
Lauren E
LE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18